Search clinical trials for: Rivaroxaban (Xarelto)

Total 547 results

Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR); Canadian Venous Thromboembolism...

Recruiting

COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation (COBRRA-AF)

Atrial Fibrillation

Canada
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR); Canadian Venous Thromboembolism...

Completed

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban (COBRRA Pilot)

Venous Thromboembolism

Canada
Brigham and Women's Hospital

Completed

Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data

Venous Thromboembolism | Pulmonary Embolism | DVT

United States
Bayer
Janssen Research & Development, LLC

Completed

Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet

Biological Availability

Germany
University Hospital, Montpellier

Completed

Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program (MONACO)

Non-valvular Atrial Fibrillation

France
Pirogov Russian National Research Medical University

Completed

Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis (RIDILOTT-DVT)

Deep Vein Thrombosis | Postthrombotic Syndrome

Russian Federation
Bayer

Completed

BAY59-7939 Japanese in Atrial Fibrillation (2nd)

Atrial Fibrillation

Japan
Seoul National University Hospital
Seoul National University Bundang Hospital; Daegu Catholic University Medical... and other collaborators

Unknown

Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) Study (PRAIS)

Ileofemoral Deep Vein Thrombosis

Korea, Republic of
Bayer

Completed

Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement (ODIXaHIP-OD)

Venous Thromboembolism

Italy, Spain, Denmark, Netherlands, Belgium, Austria, Germany, Poland, Sweden, Israel, Norway, United Kingdom, France
Bayer

Completed

BAY59-7939 in Atrial Fibrillation Once Daily (OD)

Atrial Fibrillation

Japan
Indiana University

Completed

RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding ((RAMBLE))

Venous Thromboembolism | Menstruation

United States
Bayer

Completed

Bioequivalence Study of Rivaroxaban

Embolism, Atrial Fibrillation and Venous Thrombosis

Japan
Bayer
Janssen Research & Development, LLC

Completed

Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions

Pharmacokinetics

Germany
AIO-Studien-gGmbH
Bayer; Charite University, Berlin, Germany

Terminated

Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients

Cancer | Venous Thromboembolism

Germany
Bayer
Janssen Research & Development, LLC

Completed

Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists (ANTENNA)

Non-Valvular Atrial Fibrillation

United Kingdom
Bayer

Completed

Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement (ODIXa-HIP2)

Venous Thromboembolism

Italy, Spain, Denmark, Netherlands, Belgium, Austria, Germany, Poland, Sweden, Israel, France, Norway, United Kingdom
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR); Canadian Venous Thromboembolism... and other collaborators

Not yet recruiting

VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy (PREVENT-GU)

Venous Thromboembolism | Urologic Cancer
Bayer
Janssen, LP

Completed

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) (REATTAIN)

Atrial Fibrillation

Sweden
Bayer
Janssen Research & Development, LLC

Completed

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy (XALIA)

Venous Thrombosis | Deep Vein Thrombosis

Switzerland, France, Germany, Hungary, Spain, Sweden, Austria, Czech Republic, Italy, Moldova, Republic of, Slovenia, Ukraine, United Kingdom, Israel, Portugal, Belgium, Denmark, Greece, Netherlands, Canada, Norway
Bayer
Janssen R&D, L.L.C.

Completed

Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Atrial Fibrillation

Japan
Bayer
Janssen Scientific Affairs, LLC

Completed

Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism (BOX-AF)

Atrial Fibrillation

Belgium
Kevin H.M. Kuo, MD, MSc, FRCPC

Recruiting

THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS) (THIS)

Sickle Cell Disease | Venous Thromboembolism | Central Venous Catheter Thrombosis

Canada
Charite University, Berlin, Germany
Bayer; Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

Terminated

Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19 (COVID-PREVENT)

COVID-19

Germany
Bayer

Completed

Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany

Venous Thromboembolism

Germany
Bayer
Janssen Research & Development, LLC

Completed

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEIN Jr)

Venous Thromboembolism

Belgium, China, Hong Kong, United States, Switzerland, Spain, Russian Federation, Singapore, Canada, Germany, Netherlands, United Kingdom, Austria, Brazil, Israel, Italy, Mexico, Turkey, France, Australia, Finland, Hungary, Japan, Arg... and more
Yokohama City University Medical Center
Yokohama City University

Unknown

Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran (RIVAL-AF)

Atrial Fibrillation

Japan
Bayer
Janssen Research & Development, LLC

Completed

Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy (XALIA LEA)

Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)

Turkey, Russian Federation, Korea, Republic of, Mexico, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Egypt, Kazakhstan, Algeria, Lebanon, Saudi Arabia, Ukraine, Jordan, Kenya, Kuwait, Morocco, Qatar, United Arab Emirates
The George Institute
Bayer; King Abdullah International Medical Research Center; George Clinical Pty... and other collaborators

Recruiting

Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK)

Cardiovascular Disease | Chronic Kidney Diseases | Dialysis-dependent Kidney Failure

Taiwan, Australia, Malaysia, Tunisia, Singapore, Canada, France, India, Saudi Arabia
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon (ReLoaDeD)

Atrial Fibrillation

Germany
Isfahan University of Medical Sciences

Unknown

Efficacy Comparison of Warfarin Versus Rivaroxaban CVT

Cerebral Venous Thrombosis

Iran, Islamic Republic of
Bayer
Janssen Research & Development, LLC

Completed

Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain (HEROIC)

Atrial Fibrillation

Spain
Bayer
Janssen Research & Development, LLC

Not yet recruiting

A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE) (XAPAEDUS)

Venous Thromboembolism | Children Under 2 Years

Spain, Sweden, Denmark, France
Bayer
Janssen Research & Development, LLC; Population Health Research Institute

Terminated

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS) (NAVIGATE ESUS)

Stroke

Denmark, France, Spain, China, United States, Switzerland, Germany, Greece, Korea, Republic of, Portugal, Japan, Israel, Canada, Australia, Turkey, Russian Federation, Sweden, Austria, Czechia, Poland, United Kingdom, Belgium, Brazil, Hungar... and more
Ottawa Heart Institute Research Corporation
Bristol-Myers Squibb; Bayer; Boehringer Ingelheim; Heart and Stroke Foundation...

Completed

Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events (BRUISECONTROL2)

Hematoma

Canada, Israel
Bayer
Janssen Pharmaceutical Companies (formerly Johnson & Johnson Pharmaceutical...

Recruiting

An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism

Venous Thromboembolism

Japan
Bayer
Janssen Research & Development, LLC

Completed

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction (CALLIPER)

Atrial Fibrillation

United States
Bayer
Janssen Scientific Affairs, LLC

Completed

Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication (SAFARI)

Atrial Fibrillation

France
Kyunghee University Medical Center

Unknown

Pleotropic Effect of New Oral Anticoagulants

Atrial Fibrillation

Korea, Republic of
Armed Forces Post Graduate Medical Institute (AFPGMI)...

Recruiting

Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial Disease

PAD - Peripheral Arterial Disease | Combined Anticoagulation and Antithrombotic Therapy

Pakistan
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF (APERITIF)

Myocardial Infarction, Acute | Left Ventricular Thrombus

France
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists

Atrial Fibrillation

Germany
André Luiz Malavasi Longo de Oliveira
Science Valley Research Institute

Recruiting

Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin (VALERIA)

Cancer | Venous Thromboembolism | Rivaroxaban | Thromboprophylaxis

Brazil
Brigham and Women's Hospital

Completed

Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data

Deep Vein Thrombosis, Pulmonary Embolus

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Completed

Study of the Therapeutic Effects of Naohuan Dan and Idebenone in Treating Mild Cognitive Impairment With Kidney Deficiency and Phlegm Stasis

Mild Cognitive Impairment

China
Hanoi Medical University
Bach Mai Hospital

Unknown

Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Using Propensity Score Matching

Thrombosis | Deep Vein Thrombosis | Surgery--Complications

Vietnam
Novartis Pharmaceuticals

Completed

Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects

Aplastic Anemia

Japan
The Young Investigator Group of Cardiovascular...

Completed

Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi (No-LVT)

Left Ventricular Thrombosis | Anticoagulants; Increased

Egypt
Green Cross Corporation
Parexel

Completed

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

Healthy Volunteers

United States
Northwestern University
National Heart, Lung, and Blood Institute (NHLBI); Medtronic

Completed

Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring (REACT COM)

Atrial Fibrillation

United States, Canada
GWT-TUD GmbH
Bayer

Completed

Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

Superficial Vein Thrombosis

Germany

Search clinical trials for: Rivaroxaban (Xarelto)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations